Swiss Authorized Representative for medical devices, choosing the right partner goes beyond having a local address

Can a Swiss Authorized Representative be, in practice, just an address printed on a label? Swissmedic’s own guidance points the other way: the address shown next to the CH-REP symbol must enable contact to be established, and stating only a P.O. box number, an e-mail address or a telephone number is not sufficient. Contactability is the floor of the role, not its purpose.

In brief. Medical devices do not undergo an official authorisation procedure in Switzerland; the CE label is recognised unilaterally, and Swissmedic concentrates its effort on market surveillance. A non-Swiss manufacturer is therefore represented in Switzerland by a designated party whose name and address must appear adjacent to the CH-REP symbol and must be genuinely reachable. From 1 July 2026, devices and systems and procedure packs placed on the Swiss market must be registered in swissdamed, with a transitional period until 31 December 2026 — and no transitional period at all for devices subject to reporting obligations for serious incidents, field safety corrective actions or trends. Those two facts, contactability and registration, are what a selection process should actually test.

Two definitions before going further. CH-REP is the designation used to identify the party representing a non-Swiss manufacturer in Switzerland; Swissmedic describes the symbol as indicating the authorised representative in Switzerland, and permits the wordings CH authorised representative, CH-REP or Authorised representative for Switzerland in its place. swissdamed is the Swiss database on medical devices operated by Swissmedic, made up of an Actors module for registering economic operators and a UDI Devices module for registering devices, IVDs, and systems and procedure packs.

The labelling rule about contactability is a useful lens for a decision many regulatory teams make quickly. Because Swiss market access for CE-marked devices rests on recognition at entry and on surveillance afterwards, appointing a representative has often been handled as a fast operational step, sometimes under time pressure and with whoever could be contracted first. Those arrangements are now being tested by registration deadlines, verification requests and the ordinary friction of post-market work.

Switzerland verifies after entry, not at the border

Swissmedic states that, unlike medicinal products, medical devices do not undergo an official authorisation procedure in Switzerland. The visible result of a compliance assessment is the CE label, which permits medical devices to be placed on the market within the EU and, based on unilateral recognition of the CE label, also in Switzerland. The authority describes its focus in this area as effective market surveillance.

Read those three statements together and the selection criterion for a representative changes shape. There is no pre-market file review in which a well-drafted dossier settles the question once and for all. Scrutiny arrives afterwards, unannounced, as correspondence, verification requests and registration checks. Whoever holds the Swiss mandate is the point where that scrutiny lands.

The legal perimeter sits in two ordinances: the Medical Devices Ordinance (MedDO, SR 812.213) and the Ordinance on In Vitro Diagnostic Medical Devices (IvDO, SR 812.219), which Swissmedic describes as setting out requirements and responsibilities for operators in the medical devices supply chain. The IvDO was issued by the Federal Council on 4 May 2022 and the published version carries amendments up to 1 July 2026 — a reminder that the framework a provider learned three years ago is not necessarily the one it is working under today. A candidate representative should be able to say, without hesitation, which version of the applicable ordinance it operates against and how it tracks amendments.

What the labelling rules reveal about the role

Swissmedic’s CH-REP guidance is unusually concrete on labelling, and each requirement carries an operational implication.

• The name and address of the authorised representative must appear adjacent to the CH-REP symbol.

• The address must enable contact to be established with the Swiss authorised representative; a P.O. box number, an e-mail address or a telephone number alone is not sufficient.

• The relative size of the symbol and the size of the name are not defined, but both must be clearly legible to the naked eye.

• Where symbols are used, they must as a rule conform to harmonised standards; where no such standard exists, the symbol must be explained in the enclosed product documentation — and in this case Swissmedic accepts the sole use of the CH-REP symbol without a description in the enclosed documentation.

• Instead of the symbol, the wordings CH authorised representative, CH-REP, or Authorised representative for Switzerland are permissible; the symbol description provided by the authority reads: indicates the authorised representative in Switzerland.

These points make a very small, very cheap test possible. Take the artwork currently approved for the Swiss market, print it at actual size, and check three things in sequence: that the representative’s name and address sit adjacent to the symbol rather than in a separate block on the reverse; that both are legible to the naked eye at that size, not only on screen at 400 per cent; and that the address is a place where correspondence physically arrives, not a mailbox reference with a phone number added underneath. A carton for a small IVD reagent kit, where panel space is scarce and artwork is often compressed late in the process, is where this check tends to fail.

Notice what the address rule is doing. It is not a formatting preference but a functional requirement: the authority wants a place where the representative can be reached. If the address you are about to print is a forwarding arrangement, verify that it still enables reliable, timely contact in practice — who opens the correspondence, how quickly it reaches a competent person, and what record is kept of it. The rule speaks about contactability; the practical exposure, however, sits with the manufacturer whose name shares the label.

The symbol description is equally instructive for manufacturers who already hold an EU mandate. It refers specifically to the authorised representative in Switzerland. The two functions are identified separately because they are separate designations under separate legal instruments, and the scope of each should be confirmed against the applicable ordinance, and with regulatory counsel where relevant, rather than assumed by analogy.

For the duty set itself, Swissmedic points to its information sheet on the obligations of economic operators in Switzerland (MU600_00_016e_MB, PDF version dated 01.05.2026). That document is public. A practical opening move in any selection process is to ask a candidate provider to walk through it clause by clause and explain, for each obligation, which of its own procedures covers it and who performs the work. Vague answers at this stage rarely improve after signature.

swissdamed turned the mandate into measurable work

The registration layer is where the difference between a capable partner and a nameplate becomes visible, because it produces records that can be checked against reality.

Swissmedic has been operating swissdamed since August 2024. The Actors module, where economic operators register and update their details, has been active since launch; the UDI Devices module went live and can be used to register medical devices, in vitro diagnostic medical devices, and systems and procedure packs. According to the published roadmap, voluntary registration of devices, systems and procedure packs has been possible since August 2025; since 1 July 2026, devices and systems and procedure packs placed on the market in Switzerland must be registered, with a transitional period until 31 December 2026. One carve-out belongs in every project plan: devices subject to reporting obligations for serious incidents, field safety corrective actions or trends have no transitional period and fall under the registration requirement from 1 July 2026.

Swissmedic also states who does the entering. Swiss manufacturers, persons who assemble systems and procedure packs, and authorised representatives must register their devices — for authorised representatives, their mandated devices — and systems and procedure packs in the UDI Devices module. Registration hygiene is therefore an attributable part of the representative’s workload rather than a courtesy service. Portfolio changes, discontinued references, new configurations and corrected UDI-DI data all have to reach the database and stay accurate there. If you are evaluating providers, a Swiss firm such as ALTRION can be appointed as authorized representative in Switzerland for medical devices and IVDs; what distinguishes one mandate holder from another is not whether registration appears on a service list, but how the provider notices that a record has gone out of date and who is named as accountable for correcting it.

A verification letter that doubles as a capability test

In September 2024, Swissmedic drew the attention of all Swiss authorised representatives and importers registered with it to the transitional provisions for legacy devices and asked them to verify their products in that respect, in a letter dated 18 September 2024. Set the substance aside for a moment and consider what the exercise demands: identifying, product by product, which items in a mandated portfolio sit under transitional provisions, and reporting back within a reasonable period.

A provider whose portfolio data lives in a shared inbox and three spreadsheets will handle that badly, slowly, or both. A provider with a controlled register — one record per device family, linked to certificate status, importer, labelling version and registration entry — treats it as a query. This is worth simulating during onboarding, because it is not hypothetical: it has already happened once, and the surveillance posture that produced it has not changed.

Six capabilities that separate a partner from an address

The following are the areas where gaps surface during audits, authority correspondence and field safety actions. None is exotic. Several are routinely absent.

• Authority interface readiness. A named contact and a named deputy, an agreed acknowledgement and response time for Swissmedic correspondence, a secure channel for transferring technical documentation, and a documented escalation route into your organisation. Ask specifically how a request arriving on a Friday afternoon in late July is handled.

• Post-market and vigilance coordination. A written intake and triage workflow for complaint and incident information reaching the representative, with a clear interface to whoever leads regulatory compliance on your side. The representative is not the place where reportability is decided; it is the place where information can be delayed. Expect a documented flow, not an informal habit of forwarding e-mails.

• Change control and labelling governance. An agreed notification trigger list covering label and instructions-for-use revisions, translations, certificate renewals, changes of notified body and changes of importer. Since the name and address next to the CH-REP symbol are prescribed content, any change on the representative’s side is itself a labelling change with lead times attached.

• Traceability and economic operator mapping. A maintained roster of importers and distributors per product family, reconciled against what appears in the swissdamed Actors and UDI Devices modules, with a stated frequency for that reconciliation.

• Quality management integration. Controlled procedures for the representative’s own activities, training records for the people performing them, deviation and corrective action handling, and retention rules that survive a change of personnel.

• Continuity and resilience. Holiday and absence cover, back-up staffing, access control and encryption for the documentation entrusted to the provider, and a defined retention period. A small team is not disqualifying; a single individual with no deputy and no documented handover is a concentration risk you are importing into your own compliance system.

Due diligence: what evidence looks like

Ask for artefacts rather than assurances. Redacted excerpts of the procedures governing authority requests and complaint intake, a sample of the periodic reporting the provider sends existing clients, and an anonymised account of one case handled end to end will tell you more than any capability statement. Ask how many mandates the firm currently holds and how they distribute across device classes and IVDs, since routine work on low-risk devices does not automatically transfer to implantable devices or high-risk diagnostics.

Competence checks should be concrete: which regulatory backgrounds the assigned staff have, which Swiss national languages are handled in-house and which are subcontracted, and how translation review is documented. Clarify how conflicts of interest are managed if the same firm also offers importer or distribution services to companies competing with you. Establish where your documentation is stored, under what access controls, whether subcontractors touch it, and what happens to it at termination — a provider that treats the handover package as leverage at contract end has told you something about how it will behave earlier.

Then run two or three small tests during onboarding. Retrieve a named version of a declaration of conformity within an agreed window. Confirm the current importer for a given product family and show the matching swissdamed entry. Run the artwork check described above and see whether the provider can explain, unprompted, why a P.O. box alone would not satisfy the guidance.

Contract design that closes gaps instead of creating them

The mandate is a legal instrument; the service agreement is where the operating model lives. Both should exist and they should not contradict each other. Map responsibilities explicitly for authority correspondence, complaint and incident information flow, field safety corrective actions, labelling updates, swissdamed data entry and maintenance, and support during market surveillance activity. Where a task is shared, name who prepares, who reviews and who approves.

Service levels worth writing down include acknowledgement and substantive response times, document retrieval times, notification triggers in both directions, and a governance meeting cadence. Add data governance: what is held on the provider’s systems, in which versions, for how long, and how superseded versions are archived rather than deleted. Add transition clauses covering the handover package, continuity while a mandate is transferred, and cooperation on registration updates during that window — a change of representative touches labelling and database records simultaneously, and both need an owner while the transfer is in progress.

Red flags manufacturers tend to notice too late

Certain answers should end a selection process early. A provider that cannot describe its complaint and incident workflow beyond forwarding messages. No controlled inventory of the documents it holds for you. Vagueness about who translates labelling content and who approves the translation. No deputy, no training records, no reporting. An unclear position on whether it will also act as your importer, with no explanation of how the roles are kept apart. And, more quietly, a price so low that it cannot plausibly fund trained regulatory staff, a maintained registration workload and holiday cover at the same time.

A weighted scorecard you can run internally

Score candidates on seven dimensions and weight them by your own risk profile rather than treating them as equal: compliance maturity evidenced by documented procedures and records; responsiveness measured during a pilot rather than promised in a proposal; device and IVD expertise relevant to your technologies and risk class; integration with your quality management system; continuity and staffing depth; transparency, including named people and candid answers about limitations; and cost realism.

The weighting shifts with context. For higher-risk and implantable devices, procedural maturity and vigilance coordination should dominate — these are also the products for which the swissdamed registration requirement from 1 July 2026 arrives without a transitional period where reporting obligations for serious incidents, field safety corrective actions or trends apply. For a broad, lower-risk portfolio moving through several importers, traceability and registration discipline matter more. For direct sales without a Swiss importer, the representative is your only Swiss-side interface, and response capability rises to the top of the list.

What to prepare on your own side

Partnerships fail from both ends. Appoint one accountable regulatory owner for the Swiss mandate instead of spreading it across three functions. Provide a controlled documentation package with an explicit version list, and agree the rules for notifying changes. Set a recurring rhythm: a periodic compliance review, one exercise per year using a realistic scenario, and verification of the importer and distributor roster against registration records. Agree a short set of indicators — response time, document retrieval time, training completion, open actions — and actually review them.

There is also a sequencing point that follows directly from the published deadlines. Registration became possible on a voluntary basis in August 2025 and mandatory for devices and systems and procedure packs placed on the Swiss market from 1 July 2026, with a transitional period running to 31 December 2026. A transitional period is a queue, not a reprieve: portfolios registered late compete for the same attention from the same people, and any data quality problem discovered in December is a problem discovered without slack. Where the carve-out applies — products subject to reporting obligations for serious incidents, field safety corrective actions or trends — there is no queue at all. Ask a candidate representative how much of its mandated portfolio it registered voluntarily before the deadline. The answer is a reasonable proxy for how it works generally.

Choosing a representative means choosing an operating model

The Swiss system recognises the CE label at the point of entry and concentrates its effort on surveillance afterwards. That design places the authorised representative exactly where the checking happens — the correspondence, the registration record, the verification request about legacy devices, the label that has to remain legible to the naked eye. Evaluate candidates on what they can execute on an ordinary working day under a deadline, ask for records rather than reassurance, write the interfaces into the agreement, and keep a named owner inside your own organisation. The address on the label is the visible end of that decision, not the decision itself.